Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites.
Read the full article: Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine //
Source: https://www.businesswire.com/news/home/20230206005219/en/Isoray-Completes-Merger-with-Viewpoint-Molecular-Targeting-to-Advance-New-Treatment-Paradigm-in-Targeted-Precision-Oncology-Medicine